

NZX Announcement

6 May 2020

Truscreen expands in China

Highlights

- **TruScreen device roll-out continues after COVID-19 restrictions lifted**
- **Four new hospitals added in Shanghai and Sichuan Province April 2020**
- **Distributor wins tender for five new hospitals to commence May 2020**
- **18% increase in hospital coverage in April/May 2020**

TruScreen Limited (NZX:TRU) (TruScreen or the “Company”) is pleased to advise that during April 2020 the TruScreen cervical screening device became operational in four new hospitals in the Shanghai Municipality and in Sichuan Province. These hospitals conducted around one hundred patient screening tests using TruScreen handheld real-time device during the month.

TruScreen’s China distributor, Beijing Siweixiangtai Tech Co., Ltd (SWXT) was also successful in securing an order for supplying the TruScreen cervical screening device to a further five hospitals, for delivery and installation in May 2020. This increases the number of hospitals actively using the TruScreen cervical screening device on a commercial basis from forty nine to fifty eight, an 18% increase over March 2020.

Further roll outs of the TruScreen cervical screening device are expected for the rest of the calendar year.

TruScreen CEO, Victoria Potarina comments, *“China continues to be our key focus and we are pleased with the current increase of hospital coverage. The adoption by these nine new hospitals of our TruScreen cervical screening system are a testament to the efficacy of the TruScreen cervical screening device. Our distributor, SWXT continues to work on the roll out of our Truscreen cervical screening programme in China, post COVID-19. We continue to see huge potential in this market.”*

This announcement has been approved by the Board.

- ENDS -

For more information, visit www.truscreen.com or contact:

TruScreen

Victoria Potarina

Chief Executive Officer

victoriapotarina@truscreen.com

Guy Robertson

Chief Financial Officer

guyrobertson@truscreen.com

About TruScreen:

TruScreen is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.



TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructures. As such, TruScreen's target market is low- and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is CE-marked and certified for use throughout Europe and CFDA-approved for sale in China. The global market potential for TruScreen is significant.

For more information, visit our website at www.truscreen.com

Watch our video on TruScreen: <http://truscreen.com/truscreen-the-company/truscreen-ultra-video/>